Clinical Oncology Next Generation Sequencing Market Size & Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Clinical Oncology Next Generation Sequencing Market Size Analysis

Global Clinical Oncology Next Generation Sequencing Market Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value
U.S.
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Screening
    1. By Value
  3. Companion Diagnostics
    1. By Value
  4. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. NGS Pre Sequencing
    1. By Value
  3. NGS Sequencing
    1. By Value
  4. NGS Data Analysis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Whole Genome Sequencing
    1. By Value
  3. Whole Exome Sequencing
    1. By Value
  4. Targeted Sequence And Re-Sequencing
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic laboratories
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value
U.K.
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Screening
    1. By Value
  3. Companion Diagnostics
    1. By Value
  4. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. NGS Pre Sequencing
    1. By Value
  3. NGS Sequencing
    1. By Value
  4. NGS Data Analysis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Whole Genome Sequencing
    1. By Value
  3. Whole Exome Sequencing
    1. By Value
  4. Targeted Sequence And Re-Sequencing
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic laboratories
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value
China
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Screening
    1. By Value
  3. Companion Diagnostics
    1. By Value
  4. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. NGS Pre Sequencing
    1. By Value
  3. NGS Sequencing
    1. By Value
  4. NGS Data Analysis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Whole Genome Sequencing
    1. By Value
  3. Whole Exome Sequencing
    1. By Value
  4. Targeted Sequence And Re-Sequencing
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic laboratories
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value
UAE
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Screening
    1. By Value
  3. Companion Diagnostics
    1. By Value
  4. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. NGS Pre Sequencing
    1. By Value
  3. NGS Sequencing
    1. By Value
  4. NGS Data Analysis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Whole Genome Sequencing
    1. By Value
  3. Whole Exome Sequencing
    1. By Value
  4. Targeted Sequence And Re-Sequencing
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic laboratories
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Screening
  1. By Value
3. Companion Diagnostics
  1. By Value
4. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. NGS Pre Sequencing
  1. By Value
3. NGS Sequencing
  1. By Value
4. NGS Data Analysis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Whole Genome Sequencing
  1. By Value
3. Whole Exome Sequencing
  1. By Value
4. Targeted Sequence And Re-Sequencing
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Diagnostic laboratories
  1. By Value
4. Others
  1. By Value
Brazil
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Screening
    1. By Value
  3. Companion Diagnostics
    1. By Value
  4. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. NGS Pre Sequencing
    1. By Value
  3. NGS Sequencing
    1. By Value
  4. NGS Data Analysis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Whole Genome Sequencing
    1. By Value
  3. Whole Exome Sequencing
    1. By Value
  4. Targeted Sequence And Re-Sequencing
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic laboratories
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Clinical Oncology Next Generation Sequencing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Illumina, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
Hoffmann-La Roche Ltd
QIAGEN N.V.
Foundation Medicine, INC.
Bio-Rad Laboratories, Inc.
PerkinElmer, Inc.
Becton, Dickinson and Company
PacBio
Oxford Nanopore Technologies plc.
Takara Bio Inc.
Zymo Research Corporation
G-know Me
PerkinElmer

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment